Summary

Location
at UCSF
Dates
study started
completion around

Description

Summary

The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD) and/or an autoinflammatory condition to receive a stem cell transplant. The researchers will look at how well the study treatments reduce inflammation and aid in the engraftment process (the process of donated stem cells traveling to the bone marrow, where they begin to make new immune cells.

"Funding Source - FDA OOPD"

Official Title

Phase 2 Study BRIDGING PRE-TRANSPLANT INFLAMMATORY DAMPENING for PRIMARY IMMUNE REGULATORY DISORDERS (BRIDGE Trial)

Keywords

Primary Immune Regulatory Disorder, Autoimmune Lymphoproliferative, Immune System Diseases, Stem Cell Transplant, Emapalumab, Fludarabine, Dexamethasone, 23-040, Fludarabine and Dexamethasone, Fludarabine and Dexamethasone (for generalized autoinflammation)

Eligibility

Locations

  • University of California, San Francisco (Data collection only) accepting new patients
    San Francisco California 94143 United States
  • Texas Children's Hospital (Data Collection) accepting new patients
    Houston Texas 77030 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Memorial Sloan Kettering Cancer Center
Links
Memorial Sloan Kettering Cancer Center
ID
NCT05787574
Phase
Phase 2 research study
Study Type
Interventional
Participants
Expecting 39 study participants
Last Updated